Engineered eglin c variants inhibit yeast and human proprotein processing proteases, Kex2 and furin.
We engineered eglin c, a potent subtilisin inhibitor, to create inhibitors for enzymes of the Kex2/furin family of proprotein processing proteases. A structural gene was synthesized that encoded "R(1)-eglin", having Arg at P(1) in the reactive site loop in place of Leu(45). Ten additional variants were created by cassette mutagenesis of R(1)-eglin. These polypeptides were expressed in Escherichia coli, purified to homogeneity, and their interactions with secreted, soluble Kex2 and furin were examined. R(1)-eglin itself was a modest inhibitor of Kex2, with a K(a) of approximately 10(7) M(-)(1). Substituting Arg (in R(4)R(1)-eglin) or Met (in M(4)R(1)-eglin) for Pro(42) at P(4) created potent Kex2 inhibitors exhibiting K(a) values of approximately 10(9) M(-)(1). R(4)R(1)-eglin inhibited furin with a K(a) of 4.0 x 10(8) M(-)(1). Introduction of Lys at P(1), in place of Arg in R(4)R(1)-eglin reduced affinity only approximately 3-fold for Kex2 but 15-fold for furin. The stabilities of enzyme-inhibitor complexes were characterized by association and dissociation rate constants and visualized by polyacrylamide gel electrophoresis. R(4)R(1)-eglin formed stable 1:1 complexes with both Kex2 and furin. However, substitution of Lys at P(2) in place of Thr(44) resulted in eglin variants that inhibited both Kex2 and furin but which were eventually cleaved (temporary inhibition). Surprisingly, R(6)R(4)R(1)-eglin, in which Arg was substituted for Gly(40) in R(4)R(1)-eglin, exhibited stable, high-affinity complex formation with Kex2 (K(a) of 3.5 x 10(9) M(-)(1)) but temporary inhibition of furin. This suggests that enzyme-specific interactions can alter the conformation of the reactive site loop, converting a permanent inhibitor into a substrate. Eglin variants offer possible avenues for affinity purification, crystallization, and regulation of proprotein processing proteases.
Komiyama
T
T
Department of Biological Chemistry, University of Michigan Medical School, Room 5413 Medical Science I, 1301 East Catherine, Ann Arbor, Michigan 48109, USA.
Fuller
R S
RS
D000595:Amino Acid Sequence; D045683:Furin; D014644:Genetic Variation; D006801:Humans; D008956:Models, Chemical; D008969:Molecular Sequence Data; D043484:Proprotein Convertases; D011485:Protein Binding; D015202:Protein Engineering; D011498:Protein Precursors / Q000378:metabolism*; D011499:Protein Processing, Post-Translational; D011506:Proteins; D029701:Saccharomyces cerevisiae Proteins; D015843:Serpins / Q000235:genetics / Q000494:pharmacology*; D013381:Subtilisins / Q000037:antagonists & inhibitors*
D011498:Protein Precursors; D011506:Proteins; D029701:Saccharomyces cerevisiae Proteins; D015843:Serpins; C028656:eglin proteinase inhibitors; D043484:Proprotein Convertases; D013381:Subtilisins; C058751:KEX2 protein, S cerevisiae; D045683:Furin